Study Evaluating the Pharmacokinetics of Keppra Extended Release (XR) in Children and Adults With Epilepsy

Completed · Phase 2

Conditions studied: Epilepsy

In brief

To study how the body absorbs, distributes, metabolises and eliminates Keppra XR in both children (12 to 16 years old) and adults (18 to 55 years old) with epilepsy.

Key facts

Study ID

NCT00961441

Run by

UCB BIOSCIENCES, Inc.

People needed

25

Starts

2009-09-01

Expected to finish

2010-03-01

Last updated by the study team

2015-08-06

Who can join

Age: 12 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects with a diagnosis of epilepsy on up to three concomitant anti-epileptic drugs
• Subjects on levetiracetam immediate release (IR) can be enrolled if on a stable dose for 7 days

You may not qualify if…

• Subjects with a history of status epilepticus within 3 months of Visit 1
• Subject has difficult venous accessibility

Where it is running

• Study site — Mobile, Alabama, United States
• Study site — Phoenix, Arizona, United States
• Study site — Little Rock, Arkansas, United States
• Study site — Fairfield, Connecticut, United States
• Study site — Bethesda, Maryland, United States
• Study site — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.